Allianz Director John Schroer discusses the recent pullback in biotech and the opportunities for turnarounds.» Read More
John Maraganore, Alnylam Pharmaceuticals president & CEO, and CNBC's Meg Tirrell, discuss the company's research into RNAi therapy, a process which turns off the gene's ability to "do something bad." Also Maraganore weighs in on drug pricing.
CNBC's Meg Tirrell provides insight to her experience getting her genome sequenced, and which companies are competing in the DNA mapping industry.
CNBC's Meg Tirrell takes a look at the future of personalized medicine, and which businesses are competing in the genome space.
CNBC's Meg Tirrell and David Hallal, Alexion Pharmaceuticals CEO, discuss the FDA's approval of the company's enzyme replacement drug Kanuma and weighs in on drug pricing.
CNBC's Meg Tirrell takes a look at advances in the Human Genome Project and the future of personalize medicine.
A $199 service from health company 23andMe gives individuals data from ancestry to risks of carrying a genetic condition.
Imagine a test that could give you a glimpse of your future… CNBC reporter Meg Tirrell underwent whole genome sequencing to map her DNA and discovered as many questions as answers.
Before testing your own genome, it helps to realize it can raise more questions than it answers.
The "Halftime Report" panelists discuss their strategies as the final three hours of the trading day begins.
Big pharma is angry over the TPP but the pact actually does more to promote drug innovation than any trade agreement in history, says this professor.
Valeant is reaching out to potential buyers for its specialty contact lens manufacturing division, according to two people familiar with the matter.
CNBC's Meg Tirrell talks to the CEO of Global Blood Therapeutics, which has been hit today after disappointing data from its new sickle cell treatment. CEO Ted Love explains what's next for the company.
CNBC's Meg Tirrell details the potential of Car-T immunotherapy as a new cancer treatment.
Agios CEO David Schenkein, presents data from nearly 300 patients with serious acute myeloid leukemia.
Gauging progress in early data for treating sickle cell, a disease which causes sickle-shaped red blood cells, with Bluebird Bio CEO Nick Leschly.
A drug meant to treat opioid overdoses gave a woman the chance to feel a sensation completely new to her: pain.
The "Fast Money" traders give their final trades of the day.
The U.S. is at a disadvantage because of this, two health-care CEOs said.
Doug Ramsey, chief investment officer at The Leuthold Group, answers investment questions from CNBC Pro subscribers.
Express Scripts announced today that it will partner with Imprimis Pharmaceuticals to provide a $1 alternative to Turing Pharmaceuticals' Daraprim. CNBC's Meg Tirrell reports.
Get the best of CNBC in your inbox